Caple CR 9200 User Manual Page 81

  • Download
  • Add to my manuals
  • Print
  • Page
    / 239
  • Table of contents
  • BOOKMARKS
  • Rated. / 5. Based on customer reviews
Page view 80
DVO Leitlinie Osteoporose 2014 Kurzfassung und Langfassung
92
Die Arbeitgruppe ist der Meinung, dass eine Basisdiagnostik bei Frauen, die mit
Aromatasehemmern behandelt werden, als Einzelfallentscheidung auch vor dem 60.
Lebensjahr möglich sein sollte.
(1) Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A,
Snowdon CF, Hall E, Bliss JM, Coombes RC; Intergroup Exemestane Study group. Skeletal
effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in
postmenopausal women with early breast cancer participating in the Intergroup Exemestane
Study (IES): a randomised controlled study. Lancet Oncol. 2007; Feb;8(2):119-27.
Evidenzgrad 1+ SIGN
(2) Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin
M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann
Oncol. 2008; Aug;19(8):1407-16. doi: 10.1093/annonc/mdn164. Epub 2008 Apr 29,
Evidenzgrad 1a Oxford
(3) Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P,
Coleman RE. Guidance for the management of breast cancer treatment-induced bone loss: A
consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008; 34 Suppl
1:S3-18. doi: 10.1016/j.ctrv.2008.03.007. Epub 2008 Jun 2. Evidenzgrad 1a Oxford
(4) Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D,
Perez EA. Risk of cancer treatment-associated bone loss and fractures among women with
breast cancer receiving aromatase inhibitors. Clin Breast Cancer. 2006; Jun;7(2):127-32.
Evidenzgrad 2b Oxford
(5) Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M,
Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS,
Cameron DA, Palmer MJ, Tu D. Late Extended Adjuvant Treatment With Letrozole
Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of
Tamoxifen. J Clin Oncol. 2008; Apr 20;26(12):1948-55. doi: 10.1200/JCO.2007.11.6798.
Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2008 Jul 20;26(21):3659. Evidenzgrad 2+
SIGN
Page view 80
1 2 ... 76 77 78 79 80 81 82 83 84 85 86 ... 238 239

Comments to this Manuals

No comments